The tyrosine kinase blocker osimertinib has been found as particularly sensitive to L861 mutations, which are a subset of lung cancer genetic alterations.New opportunities for tailored treatment strategies in lung cancer individuals have emerged by this finding.We will explore the significance of L861 mutations sensitive to osimertinib in this article and explore four critical factors that require attention to enhance its therapeutic efficacy.roughly 2-5% of lung cancer cases occur with L861 mutations, which are a form of EGFR (EGFR) mutation.The constitutive activation of EGFR, leading to unregulated cell proliferation and…
